CD47 and lymphoma: Collectively, the recombinant protein has much higher affinity for CD20 than that of CD47, so it will preferentially combine with CD20 positive lymphoma cells, so that the CD47 binding fragment will be pulled to the same CD20xCD47 double positive cells, thus avoiding the binding to the CD47 positive cells in the blood, reducing the toxicity related to CD47 targets.